We have developed this Investor Relations section to provide our investors (both existing and potential) and our other financial stakeholders with comprehensive, detailed and up to the minute information.
Syntopix One Page Summary July 2007
Syntopix Admission Document 2006
Syntopix Annual Report 2006 including Notice of Meeting and Proxy
Articles of Association 2005
View further details on the LSE website here >>
2007
2006
as at 13th February 2008
| Shareholder | No. of Shares |
% |
| Dr Rodney Harry Adams | 183,485 |
3.20% |
| Apollo Nominees Ltd | 193,000 |
3.37% |
| Chase Nominees Ltd |
225,989
|
3.94%
|
| Dr Jonanthan Howard Cove | 263,846 |
4.60% |
| Credit Suisse | 380,000 |
6.63% |
| Dr Elizabeth Anne Eady | 263,846 |
4.60% |
| Morstan Nominees Ltd | 225,989 |
3.94% |
| Ridings Early Growth Inv Co | 188,776 |
3.29% |
| Techtran Group Ltd |
1,020,885
|
17.81%
|
| University of Leeds | 390,000 |
6.80% |
| The Wellcome Trust | 519,168 |
9.06% |
| Pershing Keen Nominees Ltd |
470,371
|
8.21% |
4,325,325
|
||
| Others |
1,407,276
|
24.55% |
| Total issued share capital | 5,732,601 |
The percentage of shares not in public hands is 62.65%.
For all information about Syntopix please contact:
Dr. Stephen P. Jones - Chief Executive Officer
Email: spj@syntopix.com
Tel. +44 (0) 845 125 9204
Syntopix Group plc
The Institute of Pharmaceutical Innovation
University of Bradford
Bradford
BD7 1DP
Last updated: 13/02/2008